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Abstract
Background
The preparation of a randomized controlled trial (RCT) requires substantial resources and
the administrative processes can be burdensome. To facilitate the conduct of RCTs it is
important to better understand cost drivers. In January 2014 the enactment of the new
Swiss Legislation on Human Research (LHR) considerably changed the regulatory frame-
work in Switzerland. We assess if the new LHR was associated with change in (i) resource
use and costs to prepare an RCT, and (ii) approval times with research ethics committees
(RECs) and the regulatory authority Swissmedic.
Methods
We surveyed investigators of RCTs which were approved by RECs in 2012 or in 2016 and
asked for RCT preparation costs using a pre-specified item list. Additionally, we collected
approval times from RECs and Swissmedic.
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Results
The response rates of the investigator survey were 8.3% (19/228) for 2012 and 16.5% (47/
285) in 2016. The median preparation cost of an RCT was USD 72,400 (interquartile range
[IQR]: USD 59,500–87,700; n = 18) in 2012 and USD 72,600 (IQR: USD 42,800–169,600;
n = 35) in 2016. For single centre RCTs a median REC approval time of 82 (IQR: 49–107;
n = 38) days in 2012 and 92 (IQR: 65–131; n = 63) days in 2016 was observed. The median
Swissmedic approval time for any clinical trial was 27 (IQR: 19–51; n = 213) days in 2012
and 49 (IQR: 36–67; n = 179) days in 2016. The total duration for achieving RCT approval
from both authorities (REC and Swissmedic) in the parallel submission procedure applied in
2016 could not be assessed.
Conclusion
Based on limited data the costs to plan and prepare RCTs in Switzerland were approxi-
mately USD 72,000 in 2012 and 2016. For effective and valid research on costs and
approval times of RCTs a greater willingness to share cost information among investigators
and more collaboration between stakeholders with data linkage is necessary.
Introduction
Randomized controlled trials (RCTs) provide the most reliable evidence on therapeutic and
preventive interventions for decision-making in clinical practice and health policy [1].
Although the available evidence on RCT costs is limited, it is assumed that the administrative
burden as well as the costs for RCTs have increased substantially over the last decades [1–4].
This is problematic for two reasons: First, pharmaceutical companies argue that high prices for
new interventions are justified by the high development costs which are mostly driven by costs
for RCTs [5–7]. Second, especially for academic investigators it becomes increasingly difficult
to conduct clinical trials [2, 8]. For example, the number of trials performed dropped drasti-
cally after the introduction of The European Union Clinical Trials Directive in 2004 [8]. When
academic clinical trials are becoming unfeasible, many important clinical questions without
prospect for financial profit will remain unanswered. To improve this situation, it is important
to know what causes the burden to conduct clinical research (i.e. what are cost drivers that
hamper the planning and conduct of RCTs). However, a systematic review showed that trans-
parently available cost data for RCTs are sparse and the usefulness of the available data is lim-
ited [9].
In January 2014, the regulatory framework for clinical research in Switzerland considerably
changed with the enactment of the new law on research with human beings (Human Research
Act, HRA) and its ordinances (Swiss Legislation on Human Research, LHR) [10]. The new
LHR was implemented to protect the dignity, privacy and health of human beings involved in
research, but should also help to ensure the quality of research and improve transparency as
well as to create favourable conditions for researchers [10, 11]. There is a notion that with the
introduction of the LHR, additional administrative expenses may have occurred for some
types or parts of clinical studies (e.g. study registration, liability insurance, or clarification of
study risk category). At the same time, simplifications may have been achieved by introducing
the parallel submission process to research ethics committees (RECs) and the regulatory
authority Swissmedic (i.e. Swiss regulatory authority for drugs and medical devices) as well as
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a lead REC process which should reduce approval time for new study protocols and alleviates
inter-regional differences between RECs [10]. Furthermore, the newly introduced risk categor-
isation allows for the differentiation of low (category A) and mid- to high-risk (categories B &
C) trials (e.g. categorisation for RCTs with pharmaceutical treatments is linked to the approval
status of the studied treatment), with significant facilitations for the conduct of category A
studies that are particularly prevalent at academic institutions [12]. Before the introduction of
the LHR, RECs had 30 days from receipt of a study protocol to decide whether the study
should be approved, revised or rejected. Swissmedic also had 30 days to request revisions, and
both authorities were able to restart the deadline if revisions were necessary. Since the imple-
mentation of the new LHR, both institutions have, in parallel in case of simultaneous submis-
sion, a first phase of seven days to check if all formal requirements are met, and then an
additional 30 days to decide if a study can be approved or if amendments are required. In
some cases this deadline can be expanded (i.e. additional 15 days for RECs for multicentre
studies; 30 days for Swissmedic if a drug is used for the first time in humans or manufactured
in a new process) [13, 14].
In the present study, we aimed to assess the costs to plan and prepare RCTs in Switzerland
as well as approval times with RECs and Swissmedic. We further aimed to investigate whether
the new LHR was associated with any change in resource use and costs or in approval times.
Hence, we compared data from RCTs approved by Swiss RECs in 2012 (two years before the
introduction of the LHR) with RCTs approved in 2016 (two years after the introduction of the
LHR).
Materials and methods
This study is reported according to the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE, http://www.equator-network.org/reporting-guidelines/strobe/)
statement, as described in the supporting file (S1 File).
Study sample
For the present study we used RCT protocols that were included in the ongoing Adherence to
Standard Protocol Items: Recommendations for Interventional Trials (ASPIRE) project.
ASPIRE evaluates the reporting quality of study protocols for RCTs according to the Standard
Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement [15, 16]. We
included RCT protocols that were approved by a Swiss REC in 2012 (before the implementa-
tion of the new LHR) or 2016 (after the implementation of the new LHR). RCTs were defined
as prospective studies in which patients, or groups of patients, were randomly assigned to dif-
ferent interventions to evaluate effects on health outcomes. We excluded studies with healthy
volunteers, or primarily assessing health economic issues, as well as pilot studies, studies with
pseudo-randomisation, animal studies, and tissue bank studies. For each eligible RCT we
recorded characteristics including sponsor, funding source, number of patients, number of
study centres, number of involved countries, site of study initiation (Switzerland vs. other), if a
clinical trial unit (CTU) or contract research organisation (CRO) was involved in the RCT,
and the LHR risk category (applicable only for study protocols approved in 2016).
Estimation of resource use and costs of RCT preparation
In a previous study we had developed a comprehensive cost item list for RCTs that was further
refined in a case study on the resource use and costs of two investigator-initiated RCTs [17].
This list was sent to all principal investigators of the RCTs included in the ASPIRE project
(approved RCT protocols in 2012 or 2016), as a collection tool on resource use and costs (see
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S2 File). We informed them by letter about the purpose of the cost data collection and asked
them about resource use and costs during the preparation phase (conception, planning, and
preparation) of their respective RCT. In the first part of the item list, working time efforts for
all personnel had to be estimated for specific items (e.g. development of grant proposals, writ-
ing study protocol, communication with study sites). Investigators were also asked about salary
levels for different staff categories (this part was labelled as “optional”). On this basis, working
time estimates were translated into cost data. In the second part of the item list, investigators
were asked about fixed costs (e.g. REC fees, insurance costs, fixed costs for any kind of sup-
port). All received cost item lists filled in by investigators were checked for completeness. If
forms were incomplete (i.e. contained missing data which could potentially be provided by the
investigators; e.g. missing fixed costs), we contacted the investigators again and asked whether
the missing data could be provided. As the part on salary levels was optional, missing informa-
tion on salaries was imputed using median salaries per staff category (e.g. coordinating princi-
pal investigator, investigator, research nurse, medical staff (senior), medical staff (junior), and
information technology support).
Data on approval times
REC and Swissmedic, approval time were collected directly from these institutions. In addi-
tion, Interpharma (the association of pharmaceutical companies with research activities in
Switzerland) provided us with aggregated REC and Swissmedic approval time data collected
by pharmaceutical companies. At the level of RECs, for RCTs approved in 2012, we extracted
the dates when the protocols were submitted to a Swiss REC, when the RECs gave the first
response to the investigator, and when REC approved the RCT. For 2016, this information was
directly available from the newly introduced Business Administration System for Ethics Com-
mittees (BASEC). In 2016, all approval times for multicentre RCTs were from lead-RECs
(responsible for all issues relating to the trial; non-lead RECs check local conditions) [10];
while in 2012 the differentiation between lead- and non-lead RECs remained mostly unclear.
We also requested from Swissmedic approval time data for all RCTs that required Swissmedic
approval in 2012 and 2016. We aimed at matching Swissmedic and REC approval time data at
the RCT level, on the basis of a joint identifier. It was planned, for each RCT which required
approval from both authorities, to identify the date of the first submission (either to a Swiss
REC or to Swissmedic) and the date when both competent authorities approved the RCT, as a
basis for the calculation and descriptive statistical analysis of joint Swissmedic and REC
approval time. Finally, we received data from Interpharma on approval times of RCT protocols
at Swiss RECs and Swissmedic between 2012 and 2016. Interpharma collected these data
through a survey of Swiss pharmaceutical companies that could enter approval time data for
current clinical studies on a voluntary basis.
Analysis
In terms of reported effort for the preparation phase of RCTs, we summarised total working
time and costs (median, mean, IQR, minimum and maximum) for the RCTs approved in 2012
and 2016. All cost data were converted from Swiss Francs into USD (1 Swiss Franc = 1.018
USD; exchange rate 1. October 2018). We only included complete survey responses, except in
an analysis of item specific costs. For each applicable item of the cost item list, we calculated
the total working time effort per RCT (considering all individuals contributing to the same
item). To account for non-included time, unforeseen tasks (e.g. walking between patients or
buildings, discussing study) and for unproductive phases, we increased the calculated working
time by 30% (“non-pre-specified time”) [18]. Salaries were increased by 20% to account for
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overhead costs. Descriptive subgroup analyses were conducted: (i) by type of sponsor (i.e.
industry sponsor vs. non-industry sponsor); (ii) for single centre vs. multicentre RCTs; (iii) for
RCTs with or without CTU/CRO involvement; and (iv) by risk category (only available for
RCTs approved in 2016).
In sensitivity analyses, we calculated (i) results without adding 30% of non-pre-specified
time; (ii) results without adding 30% of non-pre-specified time and without adding 20% over-
head to salaries; and (iii) excluded all studies where we needed to impute the salaries of the
study personnel. Finally, we descriptively summarised item specific costs for the preparation
phase. For this analysis, we also included incomplete data sets whenever they reported time
efforts or costs for a given item.
In the main analyses of REC and Swissmedic approval times, we considered the entire time
period from submission to final approval. We also intended to calculate approval times cor-
rected for (disregarding) times which the sponsor required to respond to requests from the
authorities; finally, this was only possible for the data collected from Swissmedic). The differ-
ent target timelines applying to REC and Swissmedic submissions were taken into account in
the interpretation of the results [13, 14].
For the approval times collected directly from RECs, we present, for 2012 and 2016, mean,
median, 25th to 75th percentile range (IQR), minimum and maximum for the following durations:
(i) time from submission until approval by the REC; (ii) time from submission until first response
by the REC; and (iii) time from first response until date of approval by the REC. Additionally, we
conducted the same descriptive subgroup analyses as for the cost analyses. For RCTs approved in
2012, the available data did not allow us to distinguish lead RECs from non-lead RECs for multi-
centre RCTs, preventing a meaningful comparison of overall REC approval times in 2012 with
overall REC approval times in 2016. However, for the subsample of single-centre RCTs a compari-
son was sensible, and so we used a two-sided Wilcoxon rank-sum test for unpaired samples to
compare times from application to approval for single-centre RCTs in 2012 and 2016.
Swissmedic provided us with the dates of receiving a dossier, of acknowledgment of receipt,
and of the Swissmedic decision, for clinical trials in general, i.e. not specifically for RCTs.
Non-RCTs could not be identified and separated. We calculated the time from submission
until approval and provide the same descriptive statistics as stated above. Subgroup analyses
by type of sponsor according to the Swissmedic classification (i.e. industry trials vs. investiga-
tor initiated trials (IIT) vs. trials conducted by collaborative study groups) were performed.
We excluded trials which had to be submitted to the Federal Office of Public Health for further
evaluation, as we did not have information on when these were approved. The Swissmedic
data did not include an identification code that would have enabled us to match Swissmedic
and REC approval time data at the RCT level. In consequence, we had no means of assessing
combined Swissmedic and REC approval times.
Data from Interpharma are presented as received.
Results
We contacted and asked investigators of a total of 228 and 285 RCTs approved in 2012 and
2016, respectively, to provide us with data on resource use and costs for the preparation phase
of their RCTs (Fig 1). Out of the sample of RCTs initiated before the implementation of the
LHR (2012), we received preparation and planning costs for 19 RCTs (response rate: 8.3%)
that were incomplete in one case (here, all estimates of working time effort were missing). Out
of the RCTs that were approved in 2016 (after implementation of the LHR), we received a total
of 47 data sets of preparation and planning costs (response rate: 16.5%). Twelve of these were
incomplete and could only be used for the evaluation of costs of specific items.
Preparation costs for clinical trials
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In 2012, nine of the 18 RCTs with complete datasets were multicentre RCTs with a median
of three centres (IQR: 2–3 centres; max: 70 centres). None of these RCTs was international.
Two RCTs were initiated by industry sponsors and 16 by non-industry sponsors. (Table 1).
Fig 1. Flow chart summarising the collection of RCT preparation costs. Abbreviations: RCT, randomized clinical trial; ASPIRE, Adherence
to SPIrit statement REcommendations.
https://doi.org/10.1371/journal.pone.0210669.g001
Table 1. Retrospectively estimated working times and costs to plan and prepare RCTs.
2012 2016
Costs (in USD) Working time (in days) Costs (in USD) Working time (in days)
Sample
size
Median
(mean)
IQR (min-max) Median
(mean)
IQR (min-
max)
Sample
size
Median
(mean)
IQR (min-max) Median
(mean)
IQR (min-
max)
Total 18 72,431
(77,182)
59,435–87,638
(13,977–180,809)
113.1
(121.7)
51.3–189.8
(20.8–241.8)
35 72,631
(111,602)
42,611–169,540
(11,907–366,653)
132.6
(192.4)
79.3–239.2
(37.7–971.1)
Single centre 9 74,289
(78,560)
59,435–87,638
(13,977–180,809)
143.0
(132.6)
82.6–189.8
(24.1–211.9)
26 62,253
(91,392)
36,811–151,931
(11,907–260,458)
106.0
(156.8)
58.5–217.6
(37.7–458.9)
Multicentre 9 67,704
(76,709)
50,140–101,048
(13,977–180,809)
106.6
(110.7)
51.3–126.1
(20.8–241.8)
9 140,483
(169,983)
87,543–221,030
(62,077–366,653)
193.7
(295.5)
132.6–288.6
(92.3–971.1)
Non-industry 16 67,704
(76,709)
50,140–101,048
(13,977–180,809)
107.9
(112.3)
45.2–164.5
(20.8–241.8)
31 72,631
(117,727)
44,058–176,534
(11,907–366,653)
135.2
(202.7)
80.6–288.6
(39.7–971.1)
Industry 2 80,963
(80,963)
74,289–87,638
(74,289–87,638)
196.3
(196.3)
189.8–202.8
(189.8–202.8)
4 57,581
(64,130)
36,624–91,637
(31,665–109,692)
72.5 (87.9) 39.4–136.5
(37.7–169.0)
No CTU
involvement
11 79,731
(88,262)
59,435–128,845
(13,977–180,809)
143.0
(143.4)
68.9–211.9
(24.1–241.8)
20 73,106
(101,090)
44,192–140,917
(28,609–260,458)
133.9
(177.8)
89.4–228.8
(41.0–500.5)
With CTU
involvement
7 60,388
(59,770)
40,844–73,609
(37,953–74,289)
82.6 (87.5) 39.0–109.2
(20.8–202.8)
8 52,645
(114,124)
26,931–187,638
(11,907–366,653)
76.1
(235.0)
49.4–310.3
(37.7–971.1)
Risk category A NA - - - - 29 73,582
(111,801)
44,058–169,540
(11,907–295,515)
135.2
(180.3)
86.5–239.2
(39.7–500.5)
Risk category B NA - - - - 3 70,914
(153,255)
22,198–366,653
(22,198–366,653)
79.3
(368.8)
55.9–971.1
(55.9–971.1)
Risk category C NA - - 3 62,679
(68,012)
31,665–109,692
(31,665–109,692)
93.6
(100.1)
37.7–169.0
(37.7–169.0)
Abbreviations: CTU = clinical trial unit; IQR = interquartile range; min = minimum; max = maximum; NA = not applicable.
https://doi.org/10.1371/journal.pone.0210669.t001
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For 2016, we received complete datasets for nine multicentre (median of 3 centres; IQR: 2–6
centres; max: 7 centres; including 2 international RCTs) and 26 single centre RCTs. Four
RCTs were initiated by industry sponsors and 31 by non-industry sponsors. In 2012, the prep-
aration phase of RCTs required, in the median, 113 days (IQR: 51–190 days) in 2012 and 133
working days (IQR: 79–239 days) in 2016 (Table 1). The median costs to plan and prepare an
RCT were around USD 72,000 in 2012 as well as in 2016. Results stratified by study character-
istics (i.e. single centre, multicentre, industry, non-industry, CTU involvement, no CTU-
involvement and different risk categories) are presented in Table 1. Median costs remained rel-
atively stable across strata, except in the case of multicentre RCTs in 2016 (USD 141,000 based
on nine RCTs). Results from the sensitivity analyses are presented in Table 2. Excluding stud-
ies where we needed to impute salaries (Table 2, scenario 3) led to a substantially decreased
cost estimate for 2016 (USD 56,000 based on 14 RCTs). Costs per item were, in general, com-
parable between 2012 and 2016 (Table 3). It is interesting to note that, while protocol and case
report form development contributed most to the RCT preparation costs (i.e. median of USD
34,774 in 2012 and USD 39,503 in 2016), other items of less obvious relevance also resulted in
considerable costs (e.g. communication [median of USD 7,322 in 2012 and USD 6,506 in
2016], staff training [median of USD 3,316 in 2012 and USD 2,913 in 2016], site management
[median of USD 3,787 in 2012 and USD 6,175 in 2016]).
We collected approval time data from Swiss RECs for a total of 183 and 217 RCTs in 2012
and 2016, respectively. Approximately half of the included RCTs were industry-sponsored and
more than two thirds were multicentre (Table 4). The vast majority of approved multicentre
RCTs were international; only 23 (16%) in 2012 and 33 (22%) in 2016 focused exclusively on
Switzerland. In 2016 there were 99 (45.6%) risk category A, 50 (23.0%) risk category B, and 68
(31.3%) risk category C RCTs.
The median time from REC submission to approval was 72 (IQR: 41–107) days in 2012 and
109 (IQR: 79–154) days in 2016 (Table 4). The duration from submission until first response
from the REC was 25 (IQR: 18–42) days in 2012 (information missing for 20 studies) and 36
(IQR: 27–49) days in 2016 (S1 Table). The duration from first response from the REC until
final approval was 42 (IQR: 16–76) days in 2012 (information missing for 20 studies) and 63
Table 2. Sensitivity analysis results regarding retrospectively estimated working times and costs to plan and prepare RCTs.
2012 2016
n Median (mean) IQR (min-max) n Median (mean) IQR (min-max)
Total working time (in days)
Main analysis 18 113.1 (121.7) 51.3–189.8 (20.8–241.8) 35 132.6 (189.6) 79.3–239.2 (37.7–971.1)
Scenario 1 18 87.0 (93.6) 39.5–146.0 (16.0–186.0) 35 102.0 (145.8) 61.0–184.0 (29.0–747.0)
Scenario 2 18 87.0 (93.6) 39.5–146.0 (16.0–186.0) 35 102.0 (145.8) 61.0–184.0 (29.0–747.0)
Scenario 3 12 134.6 (135.3) 75.7–196.3 (24.1–232.7) 14 93.0 (122.6) 57.4–135.2 (37.7–500.5)
Total costs (in USD)
Main analysis 18 72,431 (77,182) 59,435–87,638 (13,977–180,809) 35 72,631 (111,602) 42,611–169,540 (11,907–366,653)
Scenario 1 18 57,458 (61,530) 45,919–68,000 (10,869–147,064) 35 58,246 (87,980) 34,078–130,651 (9,253–283,881)
Scenario 2 18 50,107 (52,834) 38,410–57,092 (9,142–128,318) 35 49,726 (74,856) 28,517–109,046 (7,779–257,681)
Scenario 3 12 75,635 (83,213) 59,744–108,241 (13,977–180,809) 14 55,596 (70,548) 31,665–87,543 (22,198–221,030)
Main analysis: +30% non-pre-specified time, +20% overhead on salaries, complete datasets but including imputed salaries.Scenario 1: +0% non-pre-specified time,
+20% overhead on salaries, complete datasets but including imputed salaries.Scenario 2: +0% non-pre-specified time, +0% overhead on salaries, complete datasets but
including imputed salaries. Scenario 3: +30% non-pre-specified time, +20% overhead on salaries, complete datasets without imputed salaries. Abbreviations: IQR = inter
quartile range; min = minimum; max = maximum.
https://doi.org/10.1371/journal.pone.0210669.t002
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(IQR: 41–106) days in 2016 (S2 Table). The data received from RECs did not allow us to sub-
tract times which sponsors required to implement requested adaptions. For the subgroup of
single-centre RCTs, the median time from submission to REC approval was 87 (IQR: 51–114)
days in 2012 and 97 (IQR: 71–141) days in 2016 (two-sided Wilcoxon rank-sum test for
unpaired samples: p = 0.043).
For 2012 we received data for 213 clinical trials and the median duration from receiving a
dossier until the final decision by Swissmedic (without counting the time which the sponsor
used to provide requested amendments) was 25 (IQR: 18–33; Table 5) days. In 2016 a total of
179 clinical trials were evaluated, with a median time to Swissmedic decision of 36 (IQR: 33–
Table 3. Item-specific costs to prepare RCTs.
2012 2016
Item-specific costs
(in USD)
n Median (mean) IQR (min-max) n Median (mean) IQR (min-max)
Protocol/forms 18 34,774 (41,457) 24,610–64,078 (6,941–76,771) 43 39,503 (61,188) 20,560–88,268 (4,116–312,007)
Budget 16 1,462 (1,859) 677–2,025 (255–5,954) 35 1,968 (4,005) 1,018–5,0489 (318–20,375)
Communication 18 7,322 (12,122) 4,621–15,126 (690–33,707) 40 6,506 (12,471) 3,048–15,253 (694–65,851)
Staff training 15 3,316 (5,103) 1,139–8,288 (725–15,113) 34 2,913 (6,088) 1,382–4,555 (136–45,850)
Site management 14 3,787 (5,441) 1,782–5,525 (255–16,621) 35 6,175 (7,993) 3,514–10,805 (442–39,932)
Database 16 2,124 (4,589) 1,450–4,558 (1,005–17,958) 35 2,487 (4,843) 1,105–4,614 (273–33,153)
Biobank setup 1 518 (518) - (-) 7 1,658 (1,633) 884–2,038 (580–3,209)
Fees 19 1,782 (2,910) 815–4,073 (509–12,831) 44 1,527 (3,124) 815–3,055 (285–19,348)
Insurance costs 4 7,452 (11,124) 3,883–18,366 (3,564–26,030) 3� 611
(883)
509–1,527 (509–1,527)
Support 7 2,037 (9,726) 815–14,664 (163–40,732) 10 3,310 (6,176) 509–6,110 (204–25,458)
Travel expenses 8 2,546 (2,712) 650–4,400 (200–6,000) 12 2,037 (2,415) 754–4,073 (20–6,110)
Other fixed costs�� 2 6,293 (6,293) 3,422–9,165 (3,422–9,165) 4 15,274 (53,589) 5,346–101,831 (509–183,296)
�These three RCTs were classified as risk category A.
��Other fixed costs referred to (if specified) piloting or amendment of the study protocol; administrative tasks; preparation of patient enrolment, intervention or
biological markers.
Abbreviations: IQR = inter quartile range; min = minimum; max = maximum.
https://doi.org/10.1371/journal.pone.0210669.t003
Table 4. Time (in days) from submission of study documents of a planned randomized clinical trial until research ethics committee approval in 2012 and 2016.
2012 2016
Sample size (%) Median (mean) IQR (min-max) Sample size (%) Median (mean) IQR (min-max)
Total 183 (100.0) 72 (85.0) 41–107 (1–329) 217 (100.0) 109 (128.6) 79–154 (20–467)
Single centre 40 (21.9) 87 (91.4) 51–113.5 (14–329) 68 (31.3) 97 (121.0) 71.2–141 (29–393)
Multicentre 143 (78.1) 70 (83.2) 38–105 (1–320) 149 (68.7) 114 (132.1) 85–155 (20–467)
National 23 (16.1)� 76 (96.3) 45–115 (1–320) 33 (22.1)� 103 (123.2) 75–135 (20–467)
International 120 (83.9)� 70 (80.7) 37.5–104 (5–301) 116 (77.9)� 120 (134.6) 87–161 (21–322)
Non-industry 89 (48.6) 67 (85.5) 35–107 (1–329) 129 (59.4) 99 (124.7) 74–145 (20–467)
Industry 94 (51.4) 81.5 (84.6) 46–106 (5–292) 88 (40.6) 117.5 (134.4) 87–162.5 (21–322)
Risk category A - - - 99 (45.6) 97 (114.6) 70–136.5 (20–467)
Risk category B - - - 50 (32.0) 110 (138.0) 85.2–158 (38–393)
Risk category C - - - 68 (31.3) 134.5 (142.1) 88–175 (50–322)
Abbreviations: IQR = interquartile range; min = minimum; max = maximum.
� Percentage refers to total of multicentre trials (n = 143).
https://doi.org/10.1371/journal.pone.0210669.t004
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38) days. Of note, for a few clinical trials submitted to Swissmedic in 2012 the date when
amendments were requested from the sponsor was not noted, hence the durations for 2012
might be overestimated. The total duration from receiving a dossier until the final decision
(not subtracting the days a sponsor used to implement requested amendments) was, in
median, 27 (IQR: 19–51) days in 2012 and 49 (IQR: 36–67) days in 2016. Combined Swissme-
dic and RECs approval times could not be assessed as explained above.
Interpharma provided data on approval times in an aggregated form for a total of 71 clinical
trials (randomized and non-randomized) in 2012 and 2013 (separate data for 2012 alone were
not available) conducted at more than 200 study sites by 14 pharmaceutical companies. The
median approval time (i.e. from first submission until final approval) at a lead REC was 64
(mean: 73; IQR: not available for Interpharma data) days and the median approval time at a
non-lead REC was 31 (mean 23) days. The median duration to obtain Swissmedic approval in
2012 and 2013 was 22 (mean 25) days. For 2016, Interpharma provided aggregated data on
approval times from 64 clinical trials conducted at approximately 180 study sites by 10 differ-
ent pharmaceutical companies. The median approval time in 2016 was 95 (mean 110) days for
a lead REC, 100 (mean 98) days for a non-lead REC, and 76 (mean 76) days for approval from
Swissmedic.
Discussion
Main findings
Reports of rapidly rising clinical trial costs worry researchers all over the globe and Dr. Clai-
borne, Director of the University of California, for instance, stated that “reducing the costs of
trials is absolutely crucial for the public good” [19]. However, to be able to identify suitable
lever-points to reduce clinical trial costs it is essential that cost data are available. This study
underlined that collecting cost data (i.e. data on resource use and preparation costs) for RCTs
in Switzerland is difficult since these data are usually not documented in a systematic way.
Based on a small sample with complete data, the median estimated costs to plan and prepare
Table 5. Swissmedic approval times by year and sponsor for clinical trials (not exclusively randomized clinical trials).
2012 2016
Sponsor Sample
size
Median
(mean)
IQR Sample
size
Median
(mean)
IQR
Approval time (in days) Swissmedic (excluding time sponsor used
to implement requested amendments)
All 213 25.0 (27.2) 17.8–
33.0
179 36.0 (37.9) 33.0–
38.0
Industry 143 22.5 (24.3) 16.0–
33.0
120 36.0 (38.0) 34.0–
37.0
IIT 52 28.0 (34.5) 20.5–
43.0
42 36.0 (36.0) 32.0–
38.3
Collaborative study
groups
18 27.0 (27.3) 17.8–
36.3
17 37.0 (41.8) 33.0–
53.0
Approval time (in days) Swissmedic (including time sponsor used
to implement requested amendments)
All 213 27.0 (48.0) 19.0–
50.5
179 49.0 (55.1) 36.0–
67.0
Industry 143 23.0 (34.1) 16.0–
50.0
120 42.0 (50.4) 36.0–
62.0
IIT 52 44.5 (85.4) 25.0–
134.0
42 56.5 (62.0) 40.5–
79.0
Collaborative study
groups
18 28.5 (56.9) 21.0–
86.5
17 72.0 (70.9) 48.0–
88.0
Abbreviations: IQR = interquartile range; IIT = Investigator initiated trial.
https://doi.org/10.1371/journal.pone.0210669.t005
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an RCT were very similar in 2012 and in 2016 (median USD 72,500), with similar ranges of
costs also at the level of individual items. These costs are substantial, especially when consider-
ing that large parts of the preparation and planning of academic RCTs are typically done
before the funding is actually secured. Specific cost items may finally not be reimbursed, as the
work was done before applying for a research grant (e.g. systematic literature search, sample
size calculation). When analysing approval times separately for the two authorities (i.e. RECs
and Swissmedic), approval times appeared to be both longer in 2016 than in 2012. Data from
industry-sponsored trials provided by Interpharma suggested an even larger difference in
approval times between 2012/2013 and 2016, which may be due to biased sample selection.
We were not able to link data from Swiss RECs (or BASEC) and Swissmedic for individual
RCTs. Therefore, combined approval times for RCTs requiring REC and Swissmedic approval
could not be assessed.
Strengths and limitations
Our study has the following strengths: It is the first study to assess working efforts and costs to
plan and conduct RCTs following an empirical and quantitative approach [9]. Furthermore,
we transparently list different items together with information about median cost which might
be helpful for other research in the planning and preparation phase of their RCTs. We evaluate
a potential impact of the Swiss LHR on RCT-associated resource use and costs, using a before
and after study design. Although we received only limited data, consistency in costs at item
level (comparing 2012 and 2016) may indicate that selection effects did not lead to major dis-
tortions in this analysis. We also made the most comprehensive effort to date to compare
approval times from competent authorities. We received approval time data from three differ-
ent sources (i.e. RECs/BASEC, Swissmedic, and Interpharma), all indicating that separate
approval times for RECs and Swissmedic were longer in 2016 compared to 2012. While
approval time data collected by Interpharma probably suffer from selection effects (voluntary
data entry by pharmaceutical companies), the data from RECs/BASEC and Swissmedic are
complete census data for 2012 and 2016 and, therefore, highly representative for Switzerland.
In terms of limitations, only a relative small sample of cost data could be retrieved. Espe-
cially with respect to industry-sponsored RCTs and RCTs approved in 2012, the achieved sam-
ple size was non-satisfactory. Thus, a distortion of the observed lack of a difference in trial
preparation costs between 2012 and 2016 due to recall problems and selection effects cannot
be ruled out. A second limitation is that a large proportion of RCTs approved in 2016 were cat-
egory A studies (99 of 217 [45.6%]). For these studies, Swissmedic approval is no longer
required under the new LHR. In 2012, this categorisation did not yet exist and all RCTs had to
undergo Swissmedic approval. Hence, the Swissmedic approval times for 2012 and 2016 can-
not necessarily be assumed to apply to the same ’population’ of RCTs, limiting comparability.
The higher risk RCTs that still require Swissmedic approval may need more time than was
needed earlier, on average. Third, it would have been important to estimate combined
approval times (from first submission to either first REC or Swissmedic until last approval by
REC or Swissmedic), given that in the trials category B and C studies still requiring Swissmedic
approval under the new LHR, submissions can be done in parallel while they had to be sequen-
tial under the old legislation. As REC and Swissmedic data did not share a common trial iden-
tification number that could have been used to match information between the sources, we
could only study REC and Swissmedic approval times separately [10]. Fourth, approval times
were retrieved differently in 2012 (directly from RECs) compared to 2016 (from BASEC).
Therefore, the 2012 sample included approval times for multicentre RCTs from lead RECs as
well as from non-lead RECs while the 2016 sample only included approval times from lead
Preparation costs for clinical trials
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RECs. We were not able to consistently distinguish lead RECs and non-lead RECs in 2012,
because the lead REC process was only partially implemented at the time. Self-reported data
from pharmaceutical companies collected by Interpharma, however, distinguished lead and
non-lead RECs already for 2012 and 2013. Fifth, we did not consider drug development phases
in our analysis since such information was not available and since the concept would not be
directly applicable to non-drug trials. The REC data did not allow us to study approval times
excluding investigator response times, other than in the case of Swissmedic. Here, the differ-
ences between 2012 and 2016 were similar irrespective of whether investigator response times
were included or excluded. Sixth, the data from Swissmedic and Interpharma also included
non-randomized trials; Swissmedic stated that the role of non-randomized trials was marginal.
Seventh, changes in approval times may also have occurred due to general differences in
approved studies (e.g. increasing numbers of dossiers may be submitted by non-Swiss compa-
nies which are not familiar with the Swiss legislation).
Comparison with similar studies
We are not aware of any other studies that investigated preparation costs for RCTs to which
we could compare our results to [9].
In terms of investigations of approval times, Heerspink and colleagues [20] conducted a
study in which they assessed if the European Union Clinical Trials Directive in 2001 facilitated
clinical drug research. To approve EU sites by authorities which adhered to the directive took
significantly longer (median 75 days) when compared with EU sites in which local legislations
applied (median 59 days). The authors concluded that the new directive “appears not to
shorten the duration of regulatory procedures within Europe”. However, it remained unclear
how the data were collected and how large the sample size was [20]. Another study assessed
approval times from 16 tuberculosis trials in South Africa [21]. They found median approval
times of 122 (IQR: 112–168) days for the Medicines Control Council and 60 (IQR: 33–81)
days for human research ethics committees. They concluded that the drug development phase
represented by a trial or support from a CRO had no effect on the approval time [21]. Further-
more, we identified two studies which both assessed REC approval times for a large multicen-
tre RCT [22, 23]. While Kenyon et al. described approval times only qualitatively for different
countries for the STITCH II trial (Surgical Trial in Lobar Intracerebral Haemorrhage) [22],
Lutz and colleagues found a median RECs approval time of 75 (IQR: 42–150) days [23]. These
published approval times are all in a similar range as found in our study, suggesting similar
processes and challenges internationally.
Conclusions
We found that the preparation costs of RCTs in Switzerland were approximately USD 72,000
in 2012 and in 2016. We believe that these costs are high for academic researchers when con-
sidering that several working steps may have to be taken before funding is awarded. Interest-
ingly, some items which may often be forgotten in cost calculations (such as communication,
staff training, and site management) cost several thousand USD. Approval times for single cen-
tre RCTs with Swiss RECs appeared to be longer in 2016 than in 2012. In addition, our empiri-
cal study revealed the following (1) the collection of RCT preparation cost data via a large
investigator survey was unsatisfactory with results based on a small sample and, therefore,
prone to selection, recall, and chance effects. We had the impression, that costs are often not
documented in investigator-initiated RCTs, hence it required large efforts to retrospectively
estimate the costs. Simple and freely available tools to plan and track trial costs might help to
record cost data. From several industry initiated RCTs we received the answer that they cannot
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provide us with these data due to confidentiality issues. (2) A simultaneous analysis of the true
combined REC and Swissmedic approval times for individual RCTs was not feasible, because
data from Swiss RECs (or BASEC) and those provided by Swissmedic could not be linked at
the RCT level. For effective and valid research on RCT approval times direct collaboration
between stakeholders with data linkage is necessary. (3) Available Interpharma data suggested
more extreme increases in approval times from 2012/2013 to 2016, probably due to selection
effects. In view of the pending revision of the LHR, adaptations should be considered so that
all data necessary to empirically evaluate the LHR are provided to the authority charged with
the enforcement of the HRA (i.e. the Federal Office of Public Health), with appropriate mea-
sures for data protection. Without valid empirical data, consequences and impact of the LHR
on the research enterprise in Switzerland cannot be accurately assessed.
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